NRSNW
Price:
$0.46
Market Cap:
$29.60M
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
NRSNW
According to NeuroSense Therapeutics Ltd.’s latest financial reports and current stock price. The company's current Current Ratio is 0.21. This represents a change of -53.23% compared to the average of 0.44 of the last 4 quarters.
The mean historical Current Ratio of NeuroSense Therapeutics Ltd. over the last ten years is 11.00. The current 0.21 Current Ratio has changed 88.69% with respect to the historical average. Over the past ten years (40 quarters), NRSNW's Current Ratio was at its highest in in the December 2021 quarter at 19.12. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
11.00
Median
6.08
Minimum
0.84
Maximum
24.68
Discovering the peaks and valleys of NeuroSense Therapeutics Ltd. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 214.66%
Maximum Annual Current Ratio = 24.68
Minimum Annual Increase = -80.29%
Minimum Annual Current Ratio = 0.84
Year | Current Ratio | Change |
---|---|---|
2023 | 0.84 | -80.29% |
2022 | 4.28 | -77.63% |
2021 | 19.12 | 214.66% |
2020 | 6.08 | -75.38% |
The current Current Ratio of NeuroSense Therapeutics Ltd. (NRSNW) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
8.08
5-year avg
11.00
10-year avg
11.00
NeuroSense Therapeutics Ltd.’s Current Ratio is less than NeuroSense Therapeutics Ltd. (0.21), less than Pasithea Therapeutics Corp. (14.81), less than GeoVax Labs, Inc. (4.17), greater than NLS Pharmaceutics AG (0.15), less than Cingulate Inc. (7.35),
Company | Current Ratio | Market cap |
---|---|---|
0.21 | $29.60M | |
14.81 | $3.33M | |
4.17 | $20.85M | |
0.15 | $2.84M | |
7.35 | $18.66M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeuroSense Therapeutics Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NeuroSense Therapeutics Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is NeuroSense Therapeutics Ltd.'s Current Ratio?
How is the Current Ratio calculated for NeuroSense Therapeutics Ltd. (NRSNW)?
What is the highest Current Ratio for NeuroSense Therapeutics Ltd. (NRSNW)?
What is the 3-year average Current Ratio for NeuroSense Therapeutics Ltd. (NRSNW)?
What is the 5-year average Current Ratio for NeuroSense Therapeutics Ltd. (NRSNW)?
How does the current Current Ratio for NeuroSense Therapeutics Ltd. (NRSNW) compare to its historical average?